Pharmacyclics (NASDAQ:PCYC) was upgraded by investment analysts at Lazard Capital Markets from a “neutral” rating to a “buy” rating in a note issued to investors on Wednesday, AnalystRatingsNetwork reports.
Pharmacyclics (NASDAQ:PCYC) opened at 116.79 on Wednesday. Pharmacyclics has a one year low of $44.91 and a one year high of $119.77. The stock’s 50-day moving average is $109.9 and its 200-day moving average is $91.00. The company has a market cap of $8.543 billion and a price-to-earnings ratio of 113.61.
Pharmacyclics (NASDAQ:PCYC) last announced its earnings results on Wednesday, July 31st. The company reported $0.26 EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.07) by $0.33. The company had revenue of $54.70 million for the quarter, compared to the consensus estimate of $52.00 million. Analysts expect that Pharmacyclics will post $-0.30 EPS for the current fiscal year.
Several other analysts have also recently commented on the stock. Analysts at Roth Capital raised their price target on shares of Pharmacyclics (NASDAQ:PCYC) from $120.00 to $130.00 in a research note to investors on Friday, August 30th. They now have a “buy” rating on the stock. Separately, analysts at Credit Suisse raised their price target on shares of Pharmacyclics (NASDAQ:PCYC) from $90.00 to $121.00 in a research note to investors on Friday, August 2nd. Finally, analysts at RBC Capital raised their price target on shares of Pharmacyclics (NASDAQ:PCYC) from $100.00 to $125.00 in a research note to investors on Thursday, August 1st. They now have an “outperform” rating on the stock.
Six investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $119.10.
Pharmacyclics, Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.